Original Article

You have full text access to this OnlineOpen article

Dysregulation of transforming growth factor β signaling in scleroderma: Overexpression of endoglin in cutaneous scleroderma fibroblasts

  1. A. Leask1,†,*,
  2. D. J. Abraham2,†,
  3. D. R. Finlay3,†,
  4. A. Holmes2,†,
  5. D. Pennington4,
  6. X. Shi-Wen2,
  7. Y. Chen1,
  8. K. Venstrom3,
  9. X. Dou3,
  10. M. Ponticos2,
  11. C. Black2,
  12. J. K. Jackman5,
  13. P. R. Findell1,
  14. M. K. Connolly3

Article first published online: 11 JUL 2002

DOI: 10.1002/art.10333

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 46, Issue 7, pages 1857–1865, July 2002

Additional Information

How to Cite

Leask, A., Abraham, D. J., Finlay, D. R., Holmes, A., Pennington, D., Shi-Wen, X., Chen, Y., Venstrom, K., Dou, X., Ponticos, M., Black, C., Jackman, J. K., Findell, P. R. and Connolly, M. K. (2002), Dysregulation of transforming growth factor β signaling in scleroderma: Overexpression of endoglin in cutaneous scleroderma fibroblasts. Arthritis & Rheumatism, 46: 1857–1865. doi: 10.1002/art.10333

Author Information

  1. 1

    FibroGen, Inc., South San Francisco, California

  2. 2

    Royal Free and University College Medical School, London, UK

  3. 3

    University of California, San Francisco

  4. 4

    Imperial Cancer Research Fund, London, UK

  5. 5

    Roche Bioscience, Palo Alto, California

  1. †

    Drs. Leask, Abraham, Finlay, and Holmes contributed equally to this work.

*FibroGen, Inc., 225 Gateway Boulevard, South San Francisco, CA 94080

Publication History

  1. Issue published online: 11 JUL 2002
  2. Article first published online: 11 JUL 2002
  3. Manuscript Accepted: 21 FEB 2002
  4. Manuscript Received: 16 OCT 2001

Funded by

  • NIH. Grant Number: AR-45879
  • Scleroderma Research Foundation
  • Dermatology Foundation
  • Westwood-Squibb Pharmaceuticals
  • Arthritis Research Campaign
  • The Raynaud's and Scleroderma Association Trust
  • Welton Foundation

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (573K)

REFERENCES

  • 1
    Black CM. The aetopathogenesis of systemic sclerosis. J Intern Med 1993; 234: 3–8.
    Direct Link:
  • 2
    Smith EA, Leroy EC. A possible role for transforming growth factor-beta in systemic sclerosis. J Invest Dermatol 1990; 95 Suppl 6: 125S–7S.
  • 3
    Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med 2000; 342: 1350–8.
  • 4
    Cotton SA, Herrick AL, Jayson MIV, Freemont AJ. TGFbeta: A role in systemic sclerosis? J Pathol 1998; 184: 4–6.
    Direct Link:
  • 5
    Gruschwitz M, Muller PU, Sepp N, Hofer E, Fontana A, Wick G. Transcription and expression of transforming growth factor type beta in the skin of progressive systemic sclerosis: A mediator of fibrosis? J Invest Dermatol 1990; 94: 197–203.
  • 6
    Higley H, Persichitte K, Chu S, Waegell W, Vancheeswaran R, Black C. Immunocytochemical localization and serologic detection of transforming growth factor β1: association with type I procollagen and inflammatory cell markers in diffuse and limited systemic sclerosis, morphea, and Raynaud's phenomenon. Arthritis Rheum 1994; 37: 278–88.
    Direct Link:
  • 7
    Kulozik M, Hogg A, Lankat-Buttgereit B, Krieg T. Co-localization of transforming growth factor β2 with α1(I) procollagen mRNA in tissue sections of patients with systemic sclerosis. J Clin Invest 1990; 86: 917–22.
  • 8
    Peltonen J, Kahari L, Jaakkola S, Kahari VM, Varga J, Uitto J, et al. Evaluation of transforming growth factor β and type I procollagen gene expression in fibrotic skin diseases by in situ hybridization. J Invest Dermatol 1990; 94: 365–71.
  • 9
    Sfikakis PP, McCune BK, Tsokos M, Aroni K, Vayiopoulos G, Tsokos GC. Immunohistochemical demonstration of transforming growth factor-β isoforms in the skin of patients with systemic sclerosis. Clin Immunol Immunopathol 1993; 69: 199–204.
  • 10
    Querfeld C, Eckes B, Huerkamp C, Krieg T, Sollberg SJ. Expression of TGF-beta 1, -beta 2 and -beta 3 in localized and systemic scleroderma. J Dermatol Sci 1999; 21: 13–22.
  • 11
    McWhirter A, Colosetti P, Rubin K, Miyazono K, Black C. Collagen type I is not under autocrine control by transforming growth factor-β1 in normal and scleroderma fibroblasts. Lab Invest 1994; 71: 885–94.
  • 12
    Needleman B, Choi J, Burrows-Mezu A, Fontana JA. Secretion and binding of transforming growth factor β by scleroderma and normal dermal fibroblasts. Arthritis Rheum 1990; 33: 650–6.
    Direct Link:
  • 13
    Moreland LW, Goldsmith KT, Russell WJ, Young KR Jr, Garver RI Jr. Transforming growth factor beta within fibrotic scleroderma lungs. Am J Med 1992; 93: 628–36.
  • 14
    Shiwen X, Pennington D, Holmes A, Leask A, Bradham D, Beauchamp JR, et al. Autocrine overexpression of CTGF maintains fibrosis: RDA analysis of fibrosis in systemic sclerosis. Exp Cell Res 2000; 259: 213–24.
  • 15
    Kawakami T, Ihn H, Xu W, Smith E, LeRoy C, Trojanowska M. Increased expression of TGF-β receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF-β signaling to scleroderma phenotype. J Invest Dermatol 1998; 110: 47–51.
  • 16
    Holmes A, Abraham DJ, Sa S, Shiwen X, Black CM, Leask A. CTGF and SMADs, maintenance of scleroderma phenotype is independent of SMAD signaling. J Biol Chem 2001; 276: 10594–601.
  • 17
    Leask A, Sa S, Holmes A, Shiwen X, Black CM, Abraham DJ. The control of CTGF (ccn2) gene expression in normal and scleroderma fibroblasts. Mol Pathol 2001; 54: 180–3.
  • 18
    Cheifetz S, Bellon T, Cales C, Vera S, Bernabeu C, Massague J, et al. Endoglin is a component of the transforming growth factor-β receptor system in human endothelial cells. J Biol Chem 1992; 267: 19027–30.
  • 19
    St-Jacques S, Cymerman U, Pece N, Letarte M. Molecular characterization and in situ localization of murine endoglin reveal that it is a transforming growth factor-beta binding protein of endothelial and stromal cells. Endocrinology 1994; 134: 2645–57.
  • 20
    Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581–90.
    Direct Link:
  • 21
    Abraham DJ, Shiwen X, Black CM, Sa S, Xu Y, Leask A. Tumor necrosis factor α suppresses the induction of connective tissue growth factor by transforming growth factor-β in normal and scleroderma fibroblasts. J Biol Chem 2000; 275: 15220–5.
  • 22
    Wodicka L, Dong H, Mittmann M, Ho MH, Lockhart DJ. Genome-wide expression monitoring in Saccharomyces cerevisiae. Nat Biotechnol 1997; 15: 1359–66.
  • 23
    Reiner SL, Zheng S, Corry DB, Locksley RM. Constructing polycompetitor cDNAs for quantitative PCR. J Immunol Methods 1993; 165: 37–46.
  • 24
    Mattila L, Airola K, Ahonen M, Hietarinta M, Black C, Saarialho-Kere U, et al. Activation of tissue inhibitor of metalloproteinases-3 (TIMP-3) mRNA expression in scleroderma skin fibroblasts. J Invest Dermatol 1998; 110: 416–21.
  • 25
    Bodey B, Bodey B, Siegel SE, Kaiser HE. Immunocytochemical detection of endoglin is indicative of angiogenesis in malignant melanoma. Anticancer Res 1998; 18: 2701–10.
  • 26
    Li DY, Sorensen LK, Brooke BS, Urness LD, Davis EC, Taylor DG, et al. Defective angiogenesis in mice lacking endoglin. Science 1999; 284: 1534–7.
  • 27
    McAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA, Jackson CE, et al. Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 1994; 8: 345–51.
  • 28
    Miyazono K, ten Dijke P, Heldin CH. TGF-beta signaling by Smad proteins. Adv Immunol 2000; 275: 115–57.
  • 29
    Gougos A, Letarte M. Identification of a human endothelial cell antigen with monoclonal antibody 44G4 produced against a pre-B leukemic cell line. J Immunol 1988; 141: 1925–33.
  • 30
    Westphal JR, Willems HW, Schalkwijk CJM, Ruiter DJ, de Waal RMW. A new 180-kDa dermal endothelial cell activation antigen: in vitro and in situ characteristics. J Invest Dermatol 1993; 100: 27–34.
  • 31
    Fonsatti E, Del Vecchio L, Altomonte M, Sigalotti L, Nicotra MR, Coral S, et al. Endoglin: an accessory component of the TGF-beta-binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies. J Cell Physiol 2001; 188: 1–7.
    Direct Link:
  • 32
    Derynck R, Feng X. TGF-β receptor signaling. Biochim Biophys Acta 1997; 1333: F105–50.
  • 33
    Rulo HFC, Westphal JR, van de Kerkhof PCM, de Waal RMW, van Vlijmen IMJJ, Ruiter DJ. Expression of endoglin in psoriatic involved and uninvolved skin. J Dermatol Sci 1995; 10: 103–9.
  • 34
    Strehlow D, Korn JH. Biology of the scleroderma fibroblast. Curr Opin Rheumatol 1998; 10: 572–8.
View Full Article (HTML) Get PDF (573K)